Microarray analysis of the in vivo response of microglia to Aβ peptides in mice with conditional deletion of the prostaglandin EP2 receptor  by Johansson, Jenny U. et al.
Genomics Data 5 (2015) 268–271
Contents lists available at ScienceDirect
Genomics Data
j ou rna l homepage: ht tp : / /www. journa ls .e lsev ie r .com/genomics-data /Data in BriefMicroarray analysis of the in vivo response of microglia to Aβ peptides in
mice with conditional deletion of the prostaglandin EP2 receptorJenny U. Johansson 1, Nathaniel S. Woodling 1, Holden D. Brown, Qian Wang, Katrin I. Andreasson ⁎
Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA 94305, United States⁎ Corresponding author at: Stanford University School
Stanford, CA 94305, United States.
E-mail address: kandreas@stanford.edu (K.I. Andreass
1 Equal contributions.
http://dx.doi.org/10.1016/j.gdata.2015.06.011
2213-5960/© 2015 The Authors. Published by Elsevier Inca b s t r a c ta r t i c l e i n f oArticle history:
Received 31 May 2015
Accepted 1 June 2015
Available online 14 June 2015Amyloid-β (Aβ) peptides accumulate in the brains of patients with Alzheimer's disease (AD), where they gener-
ate a persistent inﬂammatory response from microglia, the innate immune cells of the brain. The immune
modulatory cyclooxygenase/prostaglandin E2 (COX/PGE2) pathway has been implicated in preclinical AD devel-
opment, both in human epidemiology studies and in transgenic rodent models of AD [2,3]. PGE2 signals through
four G-protein-coupled receptors, including the EP2 receptor that has been investigated for its role in mediating
the inﬂammatory and phagocytic responses to Aβ [4]. To identify transcriptional differences in microglia lacking
the EP2 receptor, we examined mice with EP2 conditionally deleted in Cd11b-expressing immune cells. We
injected Aβ peptides or saline vehicle into the brains of adult mice, isolated primary microglia, and analyzed
RNA expression by microarray. The resulting datasets were analyzed in two studies [5,6], one describing the
basal status of microglia with or without EP2 deletion, and the second study analyzing the microglial response
to Aβ. Here we describe in detail the experimental design and data analyses. The raw data from these studies
are deposited in GEO, accession GSE57181 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE57181).
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).SpeciﬁcationsOrganism/cell
line/tissueMicroglial cells from brains of 8- to 9-month-old
Cd11b-Cre EP2+/+ and Cd11b-Cre EP2ﬂ/ﬂ mice in
C57BL/6 backgroundSex Female and male, see Table 1
Sequencer or array type Affymetrix GeneChip Mouse Gene 2.0 ST
Data format Raw
Experimental factors Mice received intracerebroventricular injection of Aβ42
ﬁbrils or saline; 48 h later, the mice were sacriﬁced for
brain dissection.Experimental features Primary microglia were isolated from whole brains
using magnetic cell sorting and processed immediately
to isolate RNA.Consent N/A
Sample source location Stanford, CA1. Direct link to deposited data
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE57181.of Medicine, 1201 Welch Road,
on).
. This is an open access article under2. Experimental design, materials and methods
2.1. Experimental design
In the context of Aβ42 peptides in AD, microglia generate a po-
tent inﬂammatory response. Microglia are also intimately associated
with neurons and synapses and perform essential nonimmune func-
tions important to normal neural function. Microglial EP2 signaling
broadly regulates inﬂammatory and anti-inﬂammatory pathways
in vivo. Previous ﬁndings suggested a harmful function of microglial
EP2 signaling both in vitro and in vivo in models of Aβ42 inﬂam-
mation, with potentiation of proinﬂammatory responses, suppres-
sion of immune cell trafﬁcking and Aβ peptide clearance [1,3]. We
aimed to identify additional functions of microglial EP2 signaling
and therefore examined microglial-speciﬁc gene expression in re-
sponse to intracerebroventricular (i.c.v.) injection of Aβ42 peptides.
Aβ42 peptide injection i.c.v. not only generates a robust, long-lasting
innate immune response, but also disrupts memory consolidation,
and thus represents a model in which to test effects of microglial
EP2 on transcriptional responses. In a previous study [2], we ana-
lyzed the inﬂammatory response up to 7 days post i.c.v. injection.
Forty-eight hours was chosen for this microarray study to avoid
the immediate inﬂammatory response to the injection procedure
while still capturing early changes in gene expression that may
have subsided at later time points.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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mune responses in vivo, we generated an EP2ﬂ/− C57BL/6 J mouse line
to allow for conditional deletion of EP2. The Cd11b-Cre line, which
drives expression of Cre recombinase in the monocyte lineage (macro-
phages andmicroglia), was used to generate Cd11b-Cre EP2ﬂ/ﬂ and con-
trol Cd11b-Cre EP2+/+ C57BL/6 mice. To analyze the response to Aβ42
peptides in adult brain, we used 8–9month-oldmice, as isolation of pri-
mary microglia becomes progressively more difﬁcult at older ages.
2.2. Sample preparation and quality control
Cd11b-Cre EP2+/+ control and Cd11b-Cre EP2ﬂ/ﬂmice were admin-
istered i.c.v. injection of Aβ42 ﬁbrils (40 pmol) or saline vehicle as de-
scribed previously [2]. At 48 h after surgery, mice were sacriﬁced by
transcardiac perfusion with saline to ensure removal of blood cells
from the brain. Brainswere removed from themice and pooled, 2 brains
of the same genotype, sex, and treatment per sample. We found that
pooling samples were required to ensure adequate cell and RNA yield.
The brains were then enzymatically dissociated and microglia isolated
using magnetic CD11b microbeads (Miltenyi Biotec) according to the
manufacturer's protocol.
RNA puriﬁcation from primary microglia was performed using
TRIzol (Life Technologies) followed by the RNeasy Mini Kit (Qiagen).
RNAqualitywas assessed using a BioAnalyzer (Agilent) and determined
to be sufﬁcient for microarray analysis (RNA Integrity Number N 7.0 for
all samples). cDNA synthesis, labeling, hybridization, and scanningwere
performed by the Stanford Protein and Nucleic Acid (PAN) Facility using
GeneChip Mouse Gene 2.0 ST arrays (Affymetrix). Samples are de-
scribed in Table 1.
2.3. Microarray and data analysis
Raw microarray data were statistically analyzed using Partek soft-
ware (Partek, Inc.), using default RMA normalization and log2 transfor-
mation of data. These raw data were deposited in GEO (accession no.
GSE57181). We used Partek to perform 2-way ANOVA analysis on the
factors of Aβ treatment and genotype, with contrasts identifying the
fold-change and signiﬁcance of the Aβ-EP2 vs. Aβ-WT; Aβ-WT vs.
Veh-WT; and Veh-EP2 vs. Veh-WT comparisons. We next identiﬁed
differentially expressed genes in each contrast using an unadjusted
P value of b0.05 to capture the widest possible number of differen-
tially expressed genes. Genes that had a fold change of N1.5 between
genotypes were used for unsupervised hierarchical clustering anal-
ysis and Gene Ontology (GO) expression analysis.
The ﬁrst study [4] looked at changes in the innate inﬂammatory re-
sponse to lipopolysaccharide (LPS) and the MPTP model of Parkinson's
disease. Here we described the generation and initial analysis of theTable 1
Samples used for microarray analysis.
GEO ID ref Sample ID Genotype S
GSM1376787 Ab_EP2_1 Cd11b-Cre; EP2 f/f F
GSM1376788 Ab_EP2_2 Cd11b-Cre; EP2 f/f F
GSM1376789 Ab_EP2_3 Cd11b-Cre; EP2 f/f F
GSM1376790 Ab_WT_1 CD11b-Cre; +/+ F
GSM1376791 Ab_WT_2 CD11b-Cre; +/+ F
GSM1376792 Ab_WT_3 CD11b-Cre; +/+ F
GSM1376793 Ab_WT_4 CD11b-Cre; +/+ F
GSM1376794 Ab_WT_5 CD11b-Cre; +/+ F
GSM1376795 Ab_WT_6 CD11b-Cre; +/+ F
GSM1376796 Ab_WT_7 CD11b-Cre; +/+ F
GSM1376797 Veh_EP2_1 Cd11b-Cre; EP2 f/f M
GSM1376798 Veh_EP2_2 Cd11b-Cre; EP2 f/f F
GSM1376799 Veh_EP2_3 Cd11b-Cre; EP2 f/f F
GSM1376800 Veh_WT_1 CD11b-Cre; +/+ M
GSM1376801 Veh_WT_2 CD11b-Cre; +/+ F
GSM1376802 Veh_WT_3 CD11b-Cre; +/+ F
GSM1376803 Veh_WT_4 CD11b-Cre; +/+ Fmice with Cd11b promotor-driven immune cell deletion of EP2 and
the Cd11b-Cre EP2ﬂ/ﬂ versus Cd11b-Cre EP2+/+ saline gene expression
comparison. Quantiﬁcation of EP2mRNA in adult microglia used formi-
croarray analysis revealed a decrease of 48% in Cd11b-Cre Ep2ﬂ/ﬂ mi-
croglia. A total of 136 genes were identiﬁed that were differentially
regulated and used to create the node map. Ingenuity Pathway Analysis
(IPA, Ingenuity Systems) was used for pathway analysis. Unsupervised
hierarchical clustering revealed a striking downregulation of a majority
of microglial genes with EP2 deletion, with 116 genes signiﬁcantly
downregulated 1.5-fold and 20 genes upregulated by 1.5-fold. The prin-
cipal biological functions represented by the differentially regulated
genes included the immune response, cytoskeletal function, and cell
cycle/mitosis. Immune molecules functioning in cytokine and chemo-
kine signaling, chemotaxis and cell adhesion, and immune cell activa-
tion were signiﬁcantly downregulated. Interestingly, cell cycle and
mitosis as well as signalingmolecules involved in cell cycle progression,
cytoskeletal function, and chromatin assembly were also signiﬁcantly
downregulated. Together, the suppression of gene expression in these
biological pathways suggests a decreased inﬂammatory and prolifera-
tive state of EP2 conditional knock-outmicroglia. To further deﬁne con-
nections between immunemolecules that were regulated bymicroglial
EP2 signaling, we performed Ingenuity Pathway Analysis to deﬁne net-
works of differentially regulated immune genes (1.5-fold and greater)
that were connected to each other either through regulation of expres-
sion or protein-protein binding. Interestingly, COX-2 was highly down-
regulated with EP2 deletion, and as COX-2 catalyzes the formation of
PGH2, the precursor of PGE2 that activates the EP2 receptor, this sug-
gests a feedforward cycle inwhich EP2-mediated increases in COX-2 ex-
pression results in further production of PGE2. Thus, conditional knock-
out of microglial EP2 resulted in the downregulation of most inﬂamma-
tory genes represented in the pathway, in large part through downreg-
ulation of COX-2, which drives expression of multiple immune genes.
In the second study [5], the comparison between Aβ- versus vehicle-
injected Cd11b-Cre mice showed the Immune System Process as the
most highly enriched (enrichment score, 94.42). Therewas a 1.3 fold in-
duction of microglial EP2 in the Cd11b-Cre control genotype. Unsuper-
vised hierarchical clustering of differentially expressed genes revealed
a striking distinction between the i.c.v. Aβ and i.c.v. vehicle treatment
groups. IPA of upstream regulatory transcription factors demonstrated
2 major nodes of inﬂammatory gene regulation, Nfkb and Irf7. In this
comparison, COX-2 was highly induced in vivo in microglia from i.c.v.
Aβ42-treated mice. Database for Annotation, Visualization and Integrat-
ed Discovery (DAVID) functional annotation software (version 6.7;
NIAID, NIH) was used to identify KEGGmolecular pathways signiﬁcantly
overrepresented among lists of the 416 transcripts differentially ex-
pressed in Aβ- versus vehicle-treated Cd11b-Cre mice. This analysis re-
vealed 20 Kyoto Encyclopedia of Genes and Genomes (KEGG) pathwaysex Treatment Cells (×10^6) RIN score
emale Aβ 2.40 9.8
emale Aβ 2.40 9.9
emale Aβ 2.00 8.7
emale Aβ 2.30 9.7
emale Aβ 1.65 9.4
emale Aβ 2.30 7.0
emale Aβ 1.75 7.7
emale Aβ 1.65 8.5
emale Aβ 0.95 9.6
emale Aβ 2.75 9.0
ale Veh 1.50 9.4
emale Veh 1.90 9.1
emale Veh 1.65 9.9
ale Veh 1.12 9.8
emale Veh 1.25 9.6
emale Veh 1.50 8.6
emale Veh 1.70 10.0
Table 2
Genes regulated N 1.5-fold by both conditional EP2 deletion and Aβ treatment.
Gene symbol Gene name
Fold change
Aβ-EP2 vs. Aβ-WT
Fold change
Aβ-WT vs. Veh-WT
Mir3094 MicroRNA 3094 1.825 −1.582
Ly6c1 Lymphocyte antigen 6 complex, locus C1 1.716 −1.714
Rabggtb RAB geranylgeranyl transferase, b subunit 1.638 −1.844
Serpinb1b Serine (or cysteine) peptidase inhibitor, clade B, member 1b 1.514 −1.687
Pln Phospholamban 1.511 −1.980
Syne1 Syne1//synaptic nuclear envelope 1 1.511 −1.660
Osm Oncostatin M −1.524 1.749
Dusp1 Dual speciﬁcity phosphatase 1 −1.542 1.824
Dusp2 Dual speciﬁcity phosphatase 2 −1.570 2.139
Thap6 THAP domain containing 6 −1.602 1.839
Pmaip1 Phorbol-12-myristate-13-acetate-induced protein 1 −1.660 2.036
BC049715 cDNA sequence BC049715 −1.715 1.594
Gm20269 Predicted gene, 20269 −1.873 1.848
Il1r2 Interleukin 1 receptor, type II −1.892 2.451
Gm129 Predicted gene 129 −1.899 1.880
Fam71a Family with sequence similarity 71, member A −2.585 2.403
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ﬂammatory signaling networks. Comparison of Aβ-treated Cd11b-Cre
Ep2ﬂ/ﬂ versus Cd11b-Cre mice revealed 55 regulated genes (Tables 2
and 3), and hierarchical clustering of these genes across conditions dem-
onstrated a clear segregation of Aβ-regulated genes in Cd11b-Cre Ep2ﬂ/ﬂ
mice. Comparison of KEGG pathways revealed shared pathways between
the Aβ-treated Cd11b-Cre and vehicle-treated Cd11b-Cre groups andTable 3
Genes regulated N 1.5-fold by conditional EP2 deletion but not by Aβ treatment.
Gene symbol Gene name
Gpr114 G protein-coupled receptor 114
Lox Lysyl oxidase
Atp6v0d2 ATPase, H+ transporting, lysosomal V0 subunit D2
St8sia6 ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltra
Rdh13 Retinol dehydrogenase 13 (all-trans and 9-cis)
Mamdc2 MAM domain containing 2
Igf1 Insulin-like growth factor 1
Slc26a7 Solute carrier family 26, member 7
Gsdmc4 Gasdermin C4
2210404O09Rik RIKEN cDNA 2210404O09 gene
Tgtp2 T cell speciﬁc GTPase 2
Pdcd1 Programmed cell death 1
Cst7 cystatin F (leukocystatin)
Cd3g CD3 antigen, gamma polypeptide
Rxrg Retinoid X receptor gamma
Olfr1212 Olfactory receptor 1212
Vmn1r184 Vomeronasal 1 receptor, 184
AF529169 cDNA sequence AF529169
Olfr1052 Olfactory receptor 1052
Olfr110 Olfactory receptor 110
Olfr1313 Olfactory receptor 1313
Axl AXL receptor tyrosine kinase
Mir7-2 MicroRNA 7-2
Gm4787 Predicted gene 4787
Lpl Lipoprotein lipase
Gm4934 Predicted gene 4934
Olfr221 Olfactory receptor 221
BC031361 cDNA sequence BC031361
Mir423 MicroRNA 423
Gm10584 Predicted gene 10584
A430078I02Rik RIKEN cDNA A430078I02 gene
Hist3h2a Histone cluster 3, H2a
4933433G15Rik RIKEN cDNA 4933433G15 gene
Mir3096b MicroRNA 3096b
G530011O06Rik RIKEN cDNA G530011O06 gene
Hist4h4 Histone cluster 4, H4
4833427F10Rik RIKEN cDNA 4833427F10 gene
Ifnb1 Interferon beta 1, ﬁbroblast
G530011O06Rik RIKEN cDNA G530011O06 genebetween the vehicle-treated Cd11b-Cre Ep2ﬂ/ﬂ and vehicle-treated
Cd11b-Cre groups. The complete set of enriched KEGG pathways in the
Cd11b-Cre Ep2ﬂ/ﬂ versus Cd11b-Cre comparison included cell cycle, pro-
teolysis, and immune pathways [5]. Interestingly, themajority of differen-
tially regulated genes in the Aβ-treated Cd11b-Cre Ep2ﬂ/ﬂ versus Aβ-
treatedCd11b-Cre comparisonwere not regulatedbyAβ, butwere specif-
ically changed with microglial EP2 deletion (39 genes, Table 3). ThisFold change
Aβ-EP2 vs. Aβ-WT
Fold change
Aβ-WT vs. Veh-WT
2.413 1.453
2.232 1.227
1.924 1.166
nsfe 1.814 −1.075
1.781 −1.058
1.752 −1.335
1.727 1.148
1.701 −1.344
1.689 1.055
1.684 −1.087
1.681 1.103
1.652 1.015
1.643 1.132
1.617 1.025
1.605 1.195
1.599 1.095
1.570 −1.114
1.553 1.088
1.549 1.011
1.549 −1.291
1.540 1.009
1.537 1.464
1.524 −1.187
1.519 −1.483
1.516 1.055
−1.502 1.441
−1.505 1.137
−1.513 1.225
−1.524 1.080
−1.527 1.264
−1.532 1.380
−1.584 1.291
−1.623 1.343
−1.649 1.381
−1.671 −1.081
−1.698 1.513
−1.780 1.492
−1.876 1.443
−5.550 −1.492
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changes, Cd11b-Cre Ep2ﬂ/ﬂmicroglia engaged alternative response path-
ways. Functional annotation of these genes using DAVID revealed an en-
richment of PPAR signaling pathway genes. There were 16 genes
regulated by N1.5-fold in both the Aβ-treated Cd11b-Cre versus vehicle-
treated Cd11b-Cre comparison and the Aβ-treated Cd11b-Cre EP2ﬂ/ﬂ ver-
sus Aβ-treated Cd11b-Cre comparison (Table 2). Notably, all 16 of these
genes are regulated in opposite directions by Aβ and EP2 deletion, sug-
gesting that EP2 deletion reverses the transcriptional effects of Aβ onmi-
croglia cells. Included among these genes are the immune genes dual
speciﬁcity phosphatase 1 and 2 and interleukin 1 receptor, type II.
3. Summary
We analyzed in vivo Cd11b-Cre control and Cd11b-Cre EP2ﬂ/ﬂmouse
brain microglia gene expression by microarray and following GO expres-
sion and pathway analyses. The results are described in two publications
[4,5],and here we provide a detailed description of the experiment and
analysis, in addition to two new tables with gene changes. Of the three
comparisons, vehicle- and Aβ-treated Cd11b-Cre showed the largest
number of genes altered. Our results identify new candidates for further
study in the inﬂammatory response of microglia in AD.Acknowledgments
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